AR030310A1 - 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas - Google Patents

2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas

Info

Publication number
AR030310A1
AR030310A1 ARP010103716A ARP010103716A AR030310A1 AR 030310 A1 AR030310 A1 AR 030310A1 AR P010103716 A ARP010103716 A AR P010103716A AR P010103716 A ARP010103716 A AR P010103716A AR 030310 A1 AR030310 A1 AR 030310A1
Authority
AR
Argentina
Prior art keywords
alkyl
pyrido
pyrimidin
compounds
independently
Prior art date
Application number
ARP010103716A
Other languages
English (en)
Inventor
James Marino Hamby
Sylvester Klutchko
James Bernard Kramer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR030310A1 publication Critical patent/AR030310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas de formula (1), donde R1, R2, R5 y R6 son independientemente H, halogeno, preferiblemente Cl, alquilo de C1-6, alcoxi de C1-6, tio, tialquilo, hidroxi, alcanoilo de C1-6, -CN, -NO2, alcanoiloxi de C1-6, COOR8, -CF3, NR8R9, o (X)m-(CH2)n-NR8R9, donde R8 y R9 son independientemente H, halogeno, alquilo de C1-6, alcanoilo de C1-6, o R8 y R9 junto con el N al cual están unidos pueden completar un anillo de 3 a 7 átomos de C, que puede contener de 1 a 3 heteroátomos como N, N substituido y S, X es NH u O, m es 0 o 1, n es de 0 a 6 siempre que m y n no sean ambos, 0, R3 y R4 son independientemente alquilo de C1-6 o alquilo de C1-6 substituido, R7 es H, alquilo de C1-6, alquenilo de C2-6 o cicloalquilo de C3-6, y sus sales farmacéuticamente aceptables y solvatos. Ejemplos de estos compuestos son 6-(3, 5-dimetoxi-fenil)8-etil-2-(piridin-4-ilamino)-8H-pirido[2, 3-d]pirimidin-7-ona y 6-(3, 5- dimetoxi-fenil)-2-(2-metil-piridin-4-ilamino)-8-etil-8H-pirido[2, 3-d]pirimidin-7-ona. Se usan para preparar una composicion farmacéutica, junto con un portador, excipiente o diluyente, util para el tratamiento de angiogénesis incontrolada, cáncer, ateroesclerosis, artritis reumatoide, restenosis, psoriasis, retinopatía diabética, degeneracion macular y otras enfermedades asociadas con vasos sanguíneos aberrantes y migracion de células endoteliales (EC), regidas por el factor de crecimiento endotelial vascular (VEGF) y el de crecimiento de fibroblastos básicos (VGF). Estos compuestos y composiciones son más potentes, selectivos, biodisponibles y estables que los existentes en el arte previo.
ARP010103716A 2000-08-04 2001-08-03 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas AR030310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22308300P 2000-08-04 2000-08-04

Publications (1)

Publication Number Publication Date
AR030310A1 true AR030310A1 (es) 2003-08-20

Family

ID=22834955

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103716A AR030310A1 (es) 2000-08-04 2001-08-03 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas

Country Status (21)

Country Link
US (1) US7022711B2 (es)
EP (1) EP1307450B1 (es)
JP (1) JP2004519422A (es)
AP (1) AP1333A (es)
AR (1) AR030310A1 (es)
AT (1) ATE408613T1 (es)
AU (1) AU2001277032A1 (es)
BR (1) BR0112857A (es)
CA (1) CA2417942C (es)
DE (1) DE60135854D1 (es)
DO (1) DOP2001000227A (es)
ES (1) ES2311532T3 (es)
GT (1) GT200100158A (es)
HN (1) HN2001000171A (es)
MX (1) MXPA02011263A (es)
PA (1) PA8524101A1 (es)
PE (1) PE20020305A1 (es)
SV (1) SV2002000572A (es)
TN (1) TNSN01118A1 (es)
UY (1) UY26867A1 (es)
WO (1) WO2002012238A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000289A (es) * 2000-08-04 2003-06-06 Warner Lambert Co Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas..
AU2001298008A1 (en) * 2000-08-04 2003-04-07 Warner-Lambert Company Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido (2,3-d)pyrimidin-7-ones
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
EP1527345A2 (en) * 2002-07-29 2005-05-04 Axxima Pharmaceuticals AG Method for isolating atp binding proteins by means of immobilized protein inhibitors
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100420687C (zh) * 2002-12-20 2008-09-24 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
DE602004010206T2 (de) 2003-08-13 2008-10-09 Takeda Pharmaceutical Co. Ltd. Dipeptidyl Peptidase Inhibitoren.
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
EP2260849A1 (en) 2004-01-21 2010-12-15 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2559302C (en) 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
PT1942898E (pt) 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes
JP5122462B2 (ja) 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (ko) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101679409B (zh) 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
ES2689103T3 (es) 2010-06-30 2018-11-08 Fujifilm Corporation Nuevo derivado de nicotinamida o sal del mismo
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
ES2916220T3 (es) * 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MX2015011514A (es) 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos.
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
JP7106462B2 (ja) * 2016-07-01 2022-07-26 ジー１ セラピューティクス， インコーポレイテッド Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
TWI741155B (zh) * 2017-02-27 2021-10-01 大陸商貝達藥業股份有限公司 Ｆｇｆｒ抑制劑及其應用
SG11202101807SA (en) 2018-08-24 2021-03-30 G1 Therapeutics Inc Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
MX2020013757A (es) * 2018-09-14 2021-03-02 Abbisko Therapeutics Co Ltd Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU2001298008A1 (en) * 2000-08-04 2003-04-07 Warner-Lambert Company Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido (2,3-d)pyrimidin-7-ones
MXPA03000289A (es) * 2000-08-04 2003-06-06 Warner Lambert Co Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas..

Also Published As

Publication number Publication date
WO2002012238A2 (en) 2002-02-14
WO2002012238A3 (en) 2002-05-10
US20030220345A1 (en) 2003-11-27
TNSN01118A1 (en) 2005-11-10
UY26867A1 (es) 2001-10-25
MXPA02011263A (es) 2003-03-10
SV2002000572A (es) 2002-07-18
AP2001002230A0 (en) 2001-09-30
EP1307450A2 (en) 2003-05-07
PA8524101A1 (es) 2002-10-24
AU2001277032A1 (en) 2002-02-18
DE60135854D1 (de) 2008-10-30
EP1307450B1 (en) 2008-09-17
US7022711B2 (en) 2006-04-04
HN2001000171A (es) 2001-09-21
AP1333A (en) 2004-11-28
PE20020305A1 (es) 2002-05-09
DOP2001000227A (es) 2002-12-15
GT200100158A (es) 2002-07-18
CA2417942C (en) 2010-06-29
ATE408613T1 (de) 2008-10-15
JP2004519422A (ja) 2004-07-02
CA2417942A1 (en) 2002-02-14
BR0112857A (pt) 2005-02-09
ES2311532T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
AR030310A1 (es) 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas
US20180186785A1 (en) Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
AU2014351571B2 (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
JP6318156B2 (ja) キナーゼをモジュレートするための化合物および方法、ならびにその指標
EP2655340B1 (en) Bi-heteroaryl compounds as vps34 inhibitors
CN1325479C (zh) 嘧啶类化合物
SI2925757T1 (en) Compounds and compositions for the treatment of parasitic diseases
EA025011B1 (ru) ПУРИНЫ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ ИСПОЛЬЗОВАНИЕ И ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
AR040971A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
PE20211703A1 (es) Compuesto derivado heterotriciclico novedoso y uso del mismo
JP2016518329A (ja) キヌレニン経路の阻害剤
KR20150096769A (ko) 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
CA2805608A1 (en) Substituted imidazoquinoline derivatives as kinase inhibitors
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
BR9916906A (pt) Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto
BR9911590A (pt) Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular
US20090227575A1 (en) 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
TW201733580A (zh) Ｔｒｋ抑制劑抵抗性的癌治療劑
AR116880A1 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm
AU2016238436A1 (en) Formylated N-heterocyclic derivatives as FGFR4 inhibitors
RU2012128551A (ru) Производные этинила
PE20232046A1 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
AR060904A1 (es) Derivados de 3,4-dihidro-2h-benzo [1,4] oxazina y tiazina como inhibidores de cetp
PE122699A1 (es) Antagonistas de receptores de vitronectina
KR20240026948A (ko) 황 함유 헤테로방향족 트리사이클릭 kras 억제제

Legal Events

Date Code Title Description
FA Abandonment or withdrawal